D.A. Davidson & CO. Raises Position in Bausch Health Companies Inc (BHC)

Share on StockTwits

D.A. Davidson & CO. boosted its holdings in Bausch Health Companies Inc (NYSE:BHC) by 11.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,210 shares of the company’s stock after buying an additional 1,900 shares during the quarter. D.A. Davidson & CO.’s holdings in Bausch Health Companies were worth $336,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. NEXT Financial Group Inc acquired a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $101,000. Contravisory Investment Management Inc. acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $104,000. Quadrant Capital Group LLC increased its position in Bausch Health Companies by 25.6% during the 4th quarter. Quadrant Capital Group LLC now owns 5,950 shares of the company’s stock valued at $105,000 after purchasing an additional 1,211 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $106,000. Finally, Polaris Greystone Financial Group LLC acquired a new stake in Bausch Health Companies during the 3rd quarter valued at approximately $107,000. Institutional investors and hedge funds own 50.08% of the company’s stock.

In other Bausch Health Companies news, insider Thomas Appio purchased 25,440 shares of Bausch Health Companies stock in a transaction that occurred on Friday, December 14th. The stock was acquired at an average price of $22.96 per share, with a total value of $584,102.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 11.54% of the company’s stock.

NYSE BHC opened at $24.48 on Monday. Bausch Health Companies Inc has a 12-month low of $14.44 and a 12-month high of $28.45. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.91. The firm has a market capitalization of $8.56 billion, a P/E ratio of 6.20, a price-to-earnings-growth ratio of 0.32 and a beta of 0.63.

Several analysts have recently commented on BHC shares. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Bausch Health Companies in a research report on Tuesday, November 6th. Morgan Stanley set a $32.00 price objective on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Monday, December 17th. HC Wainwright raised shares of Bausch Health Companies from an “average” rating to a “buy” rating in a research report on Friday, December 14th. Mizuho raised their price objective on shares of Bausch Health Companies from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, November 30th. Finally, UBS Group raised shares of Bausch Health Companies to a “buy” rating in a research report on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Bausch Health Companies presently has an average rating of “Hold” and an average price target of $26.60.

TRADEMARK VIOLATION WARNING: This story was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://weekherald.com/2019/02/11/d-a-davidson-co-raises-position-in-bausch-health-companies-inc-bhc.html.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Read More: Reverse Stock Split

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply